Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience

Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience

Background. KRAS mutation is an important predictive and prognostic factor for patients receiving anti-EGFR therapy. An expanded KRAS, NRAS, BRAF, PIK3CA mutation analysis provides additional prognostic information, but its role in predicting bevacizumab efficacy is unclear. The aim of our study was...

Full description

Bibliographic Details
Main Authors: Edita Baltruškevičienė, Ugnius Mickys, Tadas Žvirblis, Rokas Stulpinas, Teresė Pipirienė Želvienė, Eduardas Aleknavičius
Format: Article
Language:English
Published: Vilnius University Press 2016-04-01
Series:Acta Medica Lituanica
Subjects:
KRAS
NRAS
BRAF
PIK3CA
colorectal cancer
bevacizumab
Online Access:https://www.journals.vu.lt/AML/article/view/21456

Internet

https://www.journals.vu.lt/AML/article/view/21456

Similar Items